Aclarion Announces Northwestern Medicine as First CLARITY Trial Site
Portfolio Pulse from
Aclarion, Inc. has announced Northwestern Medicine as the first site for its CLARITY trial, which aims to demonstrate the effectiveness of Nociscan in improving surgical outcomes and reducing costs for chronic low back pain. Nociscan uses MR Spectroscopy and Augmented Intelligence to identify pain sources.
February 06, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclarion, Inc. partners with Northwestern Medicine for the CLARITY trial, aiming to validate Nociscan's effectiveness in improving surgical outcomes and reducing costs for chronic low back pain.
The partnership with Northwestern Medicine, a leader in clinical trial research, is a significant step for Aclarion, Inc. in validating Nociscan. This could lead to increased investor confidence and potential stock price appreciation as the trial progresses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90